ALC News and Press, Alcon Inc. From 05/10/22

Alcon press release (NYSE:ALC): Q1 Non-GAAP EPS of $0.68 beats by $0.15. Revenue of $2.18B (+14.1% Y/Y) beats by $120M. 18% increase on a constant currency basis. Outook: The company now expects constant currency net sales growth to range between +9% to +11% vs. prior outlook of +7% to +9%. R...

Strong quarterly sales of $2.2 billion, up 14% or 18% constant currency Double-digit growth in net sales in both Surgical and Vision Care Updated 2022 full year outlook Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global le...

Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...

Data presented at ASCRS 2022 highlights substantial time efficiencies for cataract surgery planned with SMARTCataract—based on real-world cases 1 SMARTCataract capabilities now upgraded with connectivity to ORA SYSTEM with VerifEye+ Alcon Vision Suite ...

Data around recently launched Clareon ® IOL material showcases excellent vision and lasting clarity—three years after implantation 1 ARGOS ® Biometer with Image Guidance demonstrates significant time savings for cataract surgery planning 2-4 ...

New campaign will highlight Kate Walsh’s journey with dry eye and how finding the right solution of Systane helped her reconnect with what matters Partnership supports the launch of Systane Complete Preservative-Free, the latest addition to Alcon’s #1 doctor-re...

Alcon Board of Directors proposes to elect Raquel C. Bono, M.D. as a new Board member Shareholders asked to exercise voting rights exclusively by sending voting instructions to the independent representative due to closed format Proposed dividend of CHF 0.20 cash per...

Since my previous article on ALC, the stock is down ~10% vs. ~6% for the S&P 500 and is now fairly valued in my opinion for a 6% return. ALC delivered another solid quarter and raised its long-term revenue growth rate from ~5% to ~8%. I wouldn't exclude a further 10-20% drop o...

At first glance, shares of Meridian Bioscience look quite affordable, especially considering recent growth. But investors need to pay attention to the likely temporary improvement caused by the COVID-19 pandemic. Adjusting for this, the company looks much more expensive than it do...

Clareon family of intraocular lenses (IOLs) delivers excellent vision, exceptional clarity and predictable refractive outcomes in a glistening-free § IOL material 1-3 Long-lasting clarity of the Clareon IOL and extensive real-world experience with excellent outc...